PlatinumRx

Download App

Meningococcal Vaccine (Group A, C, Y & W-135)

Uses

Meningococcal Vaccine (Group A, C, Y & W-135) is used to prevent meningococcal disease.

How it Works

How Meningococcal Vaccine (Group A, C, Y & W-135) works Meningococcal Vaccine (Group A, C, Y & W-135) is a vaccine that helps develop immunity by initiating a mild infection. This type of infection does not cause illness but stimulates the body's immune system to produce antibodies, which are proteins that protect against future infections.

Side Effects

Common side effects of the Meningococcal Vaccine (Group A, C, Y & W-135) include headache, injection site pain, injection site redness, injection site induration (hardening of normally soft tissue or organ), irritability, sleepiness, general discomfort, muscle pain, and nausea.

Expert Advice

Meningococcal Vaccine (Group A, C, Y & W-135) is used to prevent meningococcal disease.
It is not recommended for use in infants and children under 9 months of age.
The vaccine is usually administered by injection into the muscle of the upper arm.
Your doctor will advise you if and when you should receive a booster dose.
Immunocompromised individuals or persons with functional or anatomic asplenia (including sickle cell disease) should receive the vaccine.
Individuals traveling to the US & Europe or attending Hajj (where meningococcal meningitis is more prevalent) are advised to get vaccinated with the Meningococcal Vaccine (Group A, C, Y & W-135).

Other Combinations

Diphtheria Toxoid + Meningococcal Vaccine (Group A

C

Y & W-135)

Related Medications

Salt Composition

Meningococcal Vaccine (Group A, C, Y & W-135)

Meningitis Act Injection

Sanofi India Ltd.

Vial of 1 ml

MRP

₹381.3

Sorry, the substitute medicine is Currently Unavailable

Salt Composition

Meningococcal Vaccine (Group A, C, Y & W-135)

Meningo A&C Injection

Sanofi India Ltd.

Vial of 1 ml

MRP

₹395

Sorry, the substitute medicine is Currently Unavailable

Salt Composition

Meningococcal Vaccine (Group A, C, Y & W-135)

₹518.4

Sorry, the substitute medicine is Currently Unavailable

Salt Composition

Meningococcal Vaccine (Group A, C, Y & W-135)

Mencevax Acwy Vaccine Injection 1ml

Glaxo SmithKline Pharmaceuticals Ltd.

Vial of 1 ml

MRP

₹1,050

Sorry, the substitute medicine is Currently Unavailable

Salt Composition

Meningococcal Vaccine (Group A, C, Y & W-135)

Menveo Vaccine 1s

GlaxoSmithKline Consumer Healthcare

Vial of 0

MRP

₹3,950

Sorry, the substitute medicine is Currently Unavailable

Salt Composition

Meningococcal Vaccine (Group A, C, Y & W-135)

Quadri Meningo Vaccine

Biomed Pharmaceuticals

Vial of 1 ml

MRP

₹1,150

Sorry, the substitute medicine is Currently Unavailable

Salt Composition

Meningococcal Vaccine (Group A, C, Y & W-135)

Mencevax Acwy Vaccine Injection 1s

Glaxo SmithKline Pharmaceuticals Ltd.

Vial of 1 unit

MRP

₹1,050

Sorry, the substitute medicine is Currently Unavailable

Salt Composition

Meningococcal Vaccine (Group A, C, Y & W-135) 50mcg

Quadrimeningo 50mcg Injection

Bio-Med Pvt. Ltd.

Vial of 1 ml

MRP

₹650

Sorry, the substitute medicine is Currently Unavailable

Frequently asked questions

What is the Meningococcal Vaccine (Group A, C, Y & W-135)?

The Meningococcal Vaccine (Group A, C, Y & W-135) is designed for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. It is approved for individuals aged 2 months to 55 years.

Who should avoid the Meningococcal Vaccine (Group A, C, Y & W-135)?

Individuals with a known allergy to any components of the Meningococcal Vaccine (Group A, C, Y & W-135) or similar vaccines should not receive it. Allergic reactions may include itchy rashes, shortness of breath, and facial or tongue swelling. Inform your doctor if you have a history of allergic reactions to medications.

How is the Meningococcal Vaccine (Group A, C, Y & W-135) administered?

The Meningococcal Vaccine (Group A, C, Y & W-135) should only be administered by a trained healthcare professional, typically via intramuscular injection in the upper arm or thigh for children. Follow your doctor's instructions for optimal results.

Is a booster dose of the Meningococcal Vaccine (Group A, C, Y & W-135) necessary?

Yes, a booster dose may be given to individuals aged 15 to 55 years who are at continued risk for meningococcal disease, provided at least 4 years have passed since the last dose. Consult your doctor for guidance.

Can the Meningococcal Vaccine (Group A, C, Y & W-135) cause meningococcal disease?

No, the Meningococcal Vaccine (Group A, C, Y & W-135) does not cause meningococcal disease. It stimulates your body to produce antibodies, enabling it to combat the infection if exposed in the future.

;